The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

UNITED ~~STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549~~STATES

~~FORM~~SECURITIES ~~8-K~~AND EXCHANGE COMMISSION

~~CURRENT~~WASHINGTON, ~~REPORT~~D.C. 20549

~~Pursuant~~FORM ~~to Section 13 or 15(d) of the Securities Exchange Act of 1934~~8-K

~~Date~~CURRENT ~~of Report (Date of earliest event reported) March 4, 2026~~REPORT

~~TSCAN~~Pursuant ~~THERAPEUTICS,~~to ~~INC.(Exact~~Section ~~name~~13 ofor ~~registrant as specified in its charter~~15(d)

Delaware	001-40603	82-5282075
(State or other jurisdictionof incorporation)	(Commission File Number)	(IRS EmployerIdentification No.)
830 Winter Street
Waltham, Massachusetts		02451
(Address of principal executive offices)		(Zip Code)

of the Securities Exchange Act of 1934

~~Registrant’s~~Date ~~telephone~~of ~~number,~~Report ~~including~~(Date ~~area~~of ~~code~~earliest ~~857~~event ~~399-9500~~reported) March 31, 2026

~~Not~~ ~~Applicable(Former~~TSCAN ~~name or former address~~THERAPEUTICS, ifINC. ~~changed since last report)~~

~~Check~~(Exact ~~the~~name ~~appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation~~ of ~~the~~ registrant ~~under~~as ~~any~~specified ofin ~~the~~its ~~following provisions:~~ charter)

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Delaware

001-40603

82-5282075

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

Securities registered pursuant to Section 12(b) of the Act:

830 Winter Street

Waltham, Massachusetts

02451

(Address of principal executive offices)

(Zip Code)

Title of each class		TradingSymbol(s)		Name of each exchange on which registered
Voting Common Stock, par value $0.0001 per share		TCRX		The Nasdaq Global Market, LLC

Registrant’s telephone number, including area code 857 399-9500

~~Indicate~~Not by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Applicable

~~Emerging~~(Former ~~growth~~name ~~company~~or ☒former address, if changed since last report)

IfCheck anthe ~~emerging~~appropriate ~~growth~~box ~~company,~~below ~~indicate by check mark~~ if the ~~registrant~~Form ~~has~~8-K ~~elected~~filing ~~not~~is intended to ~~use~~simultaneously satisfy the ~~extended~~filing ~~transition~~obligation ~~period~~of ~~for~~the ~~complying~~registrant ~~with~~under any ~~new or revised financial accounting standards provided pursuant to Section 13(a)~~ of the ~~Exchange~~following ~~Act. ☐~~provisions:

~~Item~~☐ ~~2.02~~Written ~~Results~~communications ofpursuant ~~Operations~~to ~~and~~Rule ~~Financial~~425 ~~Condition~~under the Securities Act (17 CFR 230.425)

On☐ ~~March~~Soliciting 4,material ~~2026,~~pursuant ~~TScan~~to ~~Therapeutics,~~Rule ~~Inc.~~14a-12 ~~issued~~under ~~a press release announcing its financial results for~~ the ~~fourth~~Exchange ~~quarter~~Act ~~and~~(17 ~~fiscal~~CFR ~~year ended December 31, 2025~~240. ~~A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8~~14a-K.12)

~~The~~☐ ~~information in this Current Report on Form 8~~Pre-Kcommencement ~~and~~communications ~~Exhibit~~pursuant ~~99.1 attached hereto is intended~~ to beRule ~~furnished and shall neither be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended~~ 14d-2(~~the “Exchange Act”~~b) ~~or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing~~ under the ~~Securities Act of 1933, as amended, or the~~ Exchange Act, ~~regardless~~(17 ofCFR ~~any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing~~240.14d-2(b))

~~Item~~☐ ~~9.01~~Pre-commencement ~~Financial~~communications ~~Statements~~pursuant ~~and~~to ~~Exhibits~~Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(db) ~~Exhibits~~of the Act:

TScan Therapeutics, Inc.

Date: April 2, 2026

/s/ Gavin MacBeath

Gavin MacBeath

Chief Executive Officer

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Voting Common Stock, par value $0.0001 per share

TCRX

The Nasdaq Global Market, LLC

Exhibit No.	Description
99.1	Press Release issued by TScan Therapeutics, Inc., dated March 4, 2026.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

~~SIGNATURES~~Emerging growth company ☒

~~Pursuant~~If toan ~~the~~emerging ~~requirements~~growth ofcompany, ~~the~~indicate ~~Securities~~by ~~Exchange~~check ~~Act~~mark ofif ~~1934,~~ the registrant has ~~duly~~elected ~~caused~~not ~~this~~to ~~report~~use tothe beextended ~~signed~~transition onperiod ~~its~~for ~~behalf~~complying bywith ~~the~~any ~~undersigned~~new ~~hereunto~~or ~~duly~~revised ~~authorized~~financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

			TScan Therapeutics, Inc.
Date:	March 4, 2026	By:	/s/ Gavin MacBeath
			Gavin MacBeath, Ph.DChief Executive Officer(Principal Executive Officer)

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 31, 2026, Leiden Dworak notified TScan Therapeutics, Inc. (the “Company”) of his decision to resign as Vice President of Finance of the Company and principal accounting officer effective April 10, 2026. There were no disagreements between the Company and Mr. Dworak relating to the Company’s operations, policies or practices.

In connection with Mr. Dworak’s resignation, the Board of Directors of the Company appointed Jason A. Amello, the Chief Financial Officer and principal financial officer of the Company, as the Company’s principal accounting officer, effective April 10, 2026.

Information regarding Mr. Amello’s background and business experience, contracts between the Company and Mr. Amello, and any related party transactions involving Mr. Amello is incorporated by reference herein from the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on May 14, 2025. Mr. Amello will not receive any additional compensation for assuming the additional role of principal accounting officer, and no changes have been made to any plans or arrangements in which Mr. Amello participates as a result of this appointment.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Filing Compare · TScan Therapeutics, Inc.